===========================================================================

                                UNITED STATES
                     SECURITIES AND EXCHANGE COMMISSION
                           Washington, D.C. 20549

                     ----------------------------------

                                  FORM 8-K

                               CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF
                     THE SECURITIES EXCHANGE ACT OF 1934

                        Commission File Number 1-9601

      Date of Report (date of earliest event reported): August 17, 2005


                         K-V PHARMACEUTICAL COMPANY
           (Exact name of registrant as specified in its charter)


            DELAWARE                                 43-0618919
 (State or other jurisdiction of          (I.R.S. Employer Identification No.)
 incorporation or organization)

      2503 SOUTH HANLEY ROAD
        ST. LOUIS, MISSOURI                              63144
 (Address of principal executive offices)             (Zip Code)



                               (314) 645-6600
            (Registrant's telephone number, including area code)

         Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:

     [ ] Written communications pursuant to Rule 425 under the Securities Act.
     [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
     [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
         Exchange Act.
     [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
         Exchange Act.


============================================================================




                          SECTION 7 - REGULATION FD


ITEM 7.01         REGULATION FD DISCLOSURE

                  Attached and incorporated herein by reference as Exhibit
99 is a press release issued by K-V Pharmaceutical Company (the "Company")
announcing that it has received notification of approvals to market one of
its proprietary products in 15 Eastern European countries or territories.
The information in this Form 8-K, including Exhibit 99 attached hereto, is
being furnished under Regulation FD and shall not be deemed "filed" for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
The Company has posted this Form 8-K on its internet website at
www.kvpharmaceutical.com. A copy of the press release is attached hereto as
Exhibit 99.


                                 *    *    *




                                    -2-




                                 SIGNATURES

                  Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.

Dated: August 18, 2005

                                  K-V PHARMACEUTICAL COMPANY



                                  By: /s/ Richard H. Chibnall
                                      -----------------------------------
                                      Richard H. Chibnall
                                      Vice President, Finance




                                    -3-